ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

IMMB Immunotech Laborator (CE)

0.0001
0.00 (0.00%)
24 Jul 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Immunotech Laborator (CE) USOTC:IMMB OTCMarkets Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.0001 0.00 01:00:00

- Current report filing (8-K)

19/09/2012 10:18pm

Edgar (US Regulatory)


 
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
September 18, 2012
Date of Report (Date of earliest event reported)
IMMUNOTECH LABORATORIES, INC.
(Exact name of registrant as specified in its charter)

         
Nevada   333-57514   95-4834274
         
(State or other jurisdiction   (Commission   (IRS Employer
of incorporation)   File Number)   Identification Number)
     
     
116 West Stocker Street, Glendale, California   91202
     
(Address of principal executive offices)   (Zip Code)
(818) 409-9091
Registrant’s telephone number, including area code

(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):
[  ]   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
[  ]   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     
[  ]   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     
[  ]   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

 

 

Item 5.02.  Departure of Directors or Principal Officers.

 

On September 17 th , 2012 Mr. Ara Ghanime sent his resignation letter to the Immunotech Board of Directors. Mr. Ara Ghanime is no longer a Director and Officer of Immunotech Laboratories.

 

 

 

 

Item 9.01                    Financial Statements and Exhibits

 
 

Exhibit

Number               Description

 
 

99.1                      Press Release

 



 
SIGNATURES
          Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
         
    IMMUNOTECH LABORATORIES, INC.
 
Date: September 18, 2012 By:   /s/ Harry Zhabilov  
    Harry Zhabilov  
    President   
 

1 Year Immunotech Laborator (CE) Chart

1 Year Immunotech Laborator (CE) Chart

1 Month Immunotech Laborator (CE) Chart

1 Month Immunotech Laborator (CE) Chart

Your Recent History

Delayed Upgrade Clock